Data Integrity Issues Lead to Warning Letter for Czech Facility

Drug GMP Report
A A
Interpharm Praha has received an FDA warning letter that cites data integrity issues at a facility in the Czech Republic.

To View This Article:

Login

Subscribe To Drug GMP Report

Buy This Article Now

Add this article to your cart for $40.00